36 results
6-K
EX-99.2
VALN
Valneva SE
26 Mar 24
Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F
6:44am
contracts, the impact of a pandemic, and changes in the regulatory environment in which Valneva operates. The occurrence of any of these risks
6-K
EX-99.1
VALN
Valneva SE
20 Mar 24
Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook
12:52pm
objectives despite a difficult economic environment. Our chikungunya vaccine IXCHIQ® became the world’s first licensed chikungunya vaccine available … intellectual property protection, the cancellation of existing contracts, the impact of a pandemic, and changes in the regulatory environment in which Valneva
6-K
EX-99.1
VALN
Valneva SE
18 Mar 24
Valneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and OrbiMed
6:44pm
, the impact of a pandemic, and changes in the regulatory environment in which Valneva operates. The occurrence of any of these risks and uncertainties could
6-K
EX-99.1
1zdva 79k3da28
15 Feb 24
Valneva Reports Full Year 2023 Revenue and Cash, Provides First 2024 Guidance
6:51am
6-K
EX-99.2
2pvhz1awm yv6oyu
21 Sep 23
Valneva Reports Half Year 2023 Financial Results and Provides Corporate Updates
10:52am
6-K
EX-99.1
i4sfaemaaqjxb5513po
10 Nov 22
Valneva Reports Nine-Month 2022 Results and Provides Corporate Updates
11:05am
6-K
EX-99.2
zo8u pdvz6i
11 Aug 22
Valneva Reports H1 2022 Results and Provides Corporate Updates
5:47pm
6-K
EX-99.4
b66g08l5 juun725
5 May 22
Current report (foreign)
4:59pm
6-K
EX-99.3
ko0olntb 0kof1c6
25 Mar 22
Valneva Reports Full Year 2021 Results and Provides Corporate Updates
7:24am
20-F
twmp7w4vzv1e
24 Mar 22
Annual report (foreign)
12:32pm
20-F
EX-10.3
vm0e14
24 Mar 22
Annual report (foreign)
12:32pm
424B4
uqs9 ul6uipm
1 Nov 21
Prospectus supplement with pricing info
4:06pm
F-1
1o0txsj8pjvxu41sfsry
26 Oct 21
Registration statement (foreign)
5:04pm
DRS
culdfztcl
20 Oct 21
Draft registration statement
12:00am
6-K
EX-99.2
detqkg3jrsqwj8u
18 Oct 21
Valneva Reports Positive Phase 3 Results for Inactivated, Adjuvanted COVID-19 Vaccine Candidate VLA2001
8:00am
6-K
EX-99.3
cqdzc
10 Aug 21
Valneva Reports H1 2021 Financial Results and Provides Business Update
5:25pm